Loteprednol etabonate (5mg)

Clinical Pharmacologist's Monograph

⚠️ Prescription Only: This medicine is Schedule H/H1. Do not self-medicate.

1. Clinical Overview

Loteprednol etabonate is a site-specific, soft corticosteroid (C-20 ester corticosteroid) designed for ophthalmic use. It is a prodrug that undergoes rapid hydrolysis to an inactive metabolite after exerting its therapeutic effect, minimizing systemic side effects. It is a potent anti-inflammatory agent with a high affinity for glucocorticoid receptors in ocular tissues.

OnsetDurationBioavailability
Therapeutic anti-inflammatory effects typically begin within hours, with peak effects observed within 2-3 days of initiation.Local duration is approximately 6-8 hours per dose, necessitating multiple daily applications for continuous effect.Negligible systemic bioavailability (<1%) following topical ocular administration due to rapid local metabolism.

2. Mechanism of Action

Loteprednol etabonate binds to cytoplasmic glucocorticoid receptors, forming a complex that translocates to the cell nucleus. It binds to glucocorticoid response elements (GREs) on DNA, modulating gene transcription. This leads to the induction of anti-inflammatory proteins (like lipocortin) and inhibition of the synthesis of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines (IL-1, IL-2, IL-6, TNF-α). It also stabilizes lysosomal membranes and inhibits macrophage migration.

3. Indications & Uses

  • Treatment of post-operative inflammation following ocular surgery
  • Treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., allergic conjunctivitis, vernal keratoconjunctivitis, episcleritis, anterior uveitis)

4. Dosage & Administration

Adult Dosage: One drop (approx. 0.05 ml of 0.5% = 5mg/ml suspension) into the affected eye(s) 4 times daily. For post-operative inflammation: Begin 24 hours after surgery and continue for 2 weeks. For other inflammations: Frequency may be reduced as inflammation subsides (e.g., to twice daily). Do not discontinue abruptly.

Administration: 1. Wash hands. 2. Shake the suspension well before use. 3. Tilt head back, pull lower eyelid down to form a pouch. 4. Instill one drop without touching the dropper tip to eye or any surface. 5. Close eyes gently for 1-2 minutes, apply gentle pressure on the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other eye drop. 7. Recap bottle tightly.

5. Side Effects

Common side effects may include:

  • Transient ocular burning/stinging on instillation
  • Blurred vision immediately after instillation
  • Foreign body sensation
  • Itching
  • Dry eye
  • Conjunctival hyperemia (redness)
  • Watering

6. Drug Interactions

DrugEffectSeverity
Other Ocular Corticosteroids (e.g., Dexamethasone, Prednisolone)Additive risk of elevated IOP, cataract formation, and infection.Major
Ocular NSAIDs (e.g., Ketorolac, Nepafenac)May increase risk of corneal adverse events (ulceration, perforation) especially post-surgery. Can be used together with monitoring.Moderate
Acetazolamide, Dorzolamide, Timolol (Anti-glaucoma drugs)Loteprednol may elevate IOP, potentially counteracting the effect of anti-glaucoma medication. Close IOP monitoring required.Moderate
Cyclosporine (ophthalmic emulsion)Potential synergistic anti-inflammatory effect. Administer at least 15 minutes apart.Minor

7. Patient Counselling

  • DO shake the bottle well before each use.
  • DO use exactly as prescribed; do not increase frequency or duration.
  • DO wait at least 5-10 minutes between instilling different eye drops.
  • DO apply nasolacrimal duct pressure (pressing inner corner of eye) for 1-2 minutes after instillation.
  • DO attend all follow-up appointments for IOP and slit-lamp examinations.
  • DON'T let the dropper tip touch your eye, fingers, or any surface.
  • DON'T wear contact lenses while using this medication or if you have an active ocular infection/inflammation.
  • DON'T share your eye drops with anyone.
  • DON'T stop using the medication abruptly without consulting your doctor.

8. Toxicology & Storage

Overdose: Topical overdose is unlikely to cause acute systemic toxicity. Symptoms would be local: severe ocular irritation, pain, blurred vision, increased IOP. Accidental oral ingestion may lead to systemic corticosteroid effects (hyperglycemia, adrenal suppression) but is unlikely from a single bottle.

Storage: Store at controlled room temperature (15°C to 25°C). Protect from light and freezing. Keep the bottle tightly closed when not in use. Discard the bottle 4 weeks after opening it (write the discard date on the bottle). Keep out of reach and sight of children.